Diffusion Pharmaceuticals, Inc. (DFFN)
| Market Cap | 14.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.98M |
| Shares Out | 2.04M |
| EPS (ttm) | -11.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,779 |
| Open | 7.08 |
| Previous Close | 7.13 |
| Day's Range | 6.91 - 7.24 |
| 52-Week Range | 5.10 - 43.00 |
| Beta | 1.64 |
| Analysts | Sell |
| Price Target | 40.80 (+490.4%) |
| Earnings Date | Aug 10, 2022 |
About DFFN
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia. [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for DFFN stock is "Sell." The 12-month stock price forecast is 40.8, which is an increase of 490.45% from the latest price.
News
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the bod...
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance t...
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance t...
5 Stocks Halted In Tuesday's Session
A circuit breaker is an automatic, temporary trading halt on specific securities when the underlying stock is experiencing times of high volatility. It is a measure to help restore and bring order to th...
Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) will effect a 1-for-50 reverse stock split of its common stock. The reverse stock split is expected to become effective and commence trading on a post-split...
Why Diffusion Pharmaceuticals Shares Are Falling
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares are trading lower by 20.83% at $0.21 after the company announced a 1-for-50 reverse stock split. Diffusion Pharmaceuticals says the reverse stock spli...
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022 Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
Topline data expected within two months
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
• Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T. • No Change to Meeting Location, Record Date, or Proposals to Be Voted Upon
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
CHARLOTTESVILLE, Va., March 21, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...
Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical On...
New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnerin...
CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance...
Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial
Third of Three TSC Oxygenation Trials Third of Three TSC Oxygenation Trials
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer
Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility
Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and In...
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
Second of Three TSC Oxygenation Trials Second of Three TSC Oxygenation Trials
Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance ...
Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference
CHARLOTTESVILLE, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies t...
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appe...
Diffusion Pharmaceuticals Issues Letter to Shareholders
CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...
Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference
Conference to Take Place Virtually, September 13-15, 2021 Conference to Take Place Virtually, September 13-15, 2021
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA's Pulmonology, Allergy, and Critical ...
Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND
Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update
CHARLOTTESVILLE, Va., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies t...
